NASDAQ · AUTL
Autolus Therapeutics plc American Depositary Share
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AUTL: Nov 10, 2026
Autolus Therapeutics plc American Depositary Share is expected to report earnings on 11/10/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.20 | $-0.22 | 2 |
| Dec 2026 | $-0.21 | $-0.20 | $-0.22 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 5, 11:00 AM EDTAll You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to BuyAutolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Sep 9, 8:21 AM EDTFDA Grants RMAT Designation To Autolus' Obe-cel For Lupus(RTTNews) – Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies has announced that the U.S. FDA has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-c
- The Motley Fool · Aug 18, 11:28 AM EDTAutolus (AUTL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 12, 4:55 AM EDTAutolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End(RTTNews) – Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, announced financial results for the second quarter reflecting approximately 119% revenue growth from AUCATZYL product sales and a narrower net loss. Autolus Therapeutics develops T cell t
- MarketBeat · Aug 11, 10:04 AM EDTAutolus Therapeutics Q2 Earnings Call HighlightsAutolus Therapeutics (NASDAQ:AUTL) reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial l
- RTTNews · Aug 11, 7:54 AM EDTAutolus Therapeutics' AUCATZYL Q2 Revenue Surges 119%; Boosts FY26 Outlook(RTTNews) – Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, has announced its operational and financial results for the second quarter ended June 30, 2026.
- RTTNews · Aug 3, 10:31 PM EDTTop Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum(RTTNews) – Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and Autolus Therapeutics, following the releas
- Zacks · Jul 8, 8:33 AM EDT3 Cancer Stocks to Watch as Oncology Innovation AcceleratesOncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
- RTTNews · Jun 23, 6:03 AM EDTTango Appoints Robert Azelby To Board Of Directors(RTTNews) – Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors.
- Zacks · Jun 10, 9:55 AM EDTAutolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Zacks · Jun 1, 9:55 AM EDTAutolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
- The Motley Fool · May 18, 9:09 AM EDTAutolus (AUTL) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Autolus Therapeutics plc American Depositary Share from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.